Incyte (INCY) – Management Comments
-
Incyte (INCY) Announces Approval of Pemazyre in Japan for Treatment of Patients with Unresectable Biliary Tract Cancer with Fibroblast Growth Factor Receptor 2 Fusion Gene, Worsening After Cancer Chem
-
Incyte (INCY) Announces Acceptance and Priority Review of sNDA for Jakafi as Treatment for Patients with Chronic Graft-Versus-Host Disease
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to INCY Stock Lookup